JMP Securities Reiterates Market Outperform on Ocular Therapeutix, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben reiterated a Market Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) and maintained a $12 price target.
June 13, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities reiterated a Market Outperform rating on Ocular Therapeutix and maintained a $12 price target.
The reiteration of the Market Outperform rating and maintenance of the $12 price target by JMP Securities analyst Jonathan Wolleben indicates a positive outlook for Ocular Therapeutix. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100